Laboratories and pathology groups who have been feeling the crunch created by reimbursement cuts under the Protecting Access to Medicare Act (PAMA) are being asked to sound off in a public survey being conducted by the National Independent Laboratory Association.
First put into effect in 2017, PAMA requires labs to report private payer data over a set period of time in an effort to help CMS establish a weighted median rate for services paid under the Clinical Laboratory Fee Schedule. The statute allows for individual tests to be reduced by up to 10 percent annually until the median rate is achieved.
The vast majority of tests fall under a three-year reporting cycle, meaning applicable labs are required to report their payer data from January to June of 2019 during the first quarter of 2020.
As NILA and other industry organizations continue to work with legislators to make PAMA’s overall effect clear, they are now seeking feedback from those directly impacted by these cuts.
Full message below:
“As the laboratory industry experiences pressure from the second 10% cut to the Clinical Laboratory Fee Schedule as a result of PAMA, NILA would like to continue to gather impact data from its members. Please take a moment to share your thoughts in this short survey if your laboratory receives any reimbursement through Medicare Part B. Congressional members and their staff continue to be interested in PAMA’s impact on the laboratory industry. Your responses will be aggregated and may be shared in conversations on Capitol Hill, but your laboratory will not be identified.”
Note on confidentiality: All information gathered will be anonymized and will not have any identifiers in public discussion. Survey results will only be accessible to NILA’s Washington representatives, CRD Associates, and Mark Birenbaum, Administrator of NILA.”